drugset / Trial / NCT04355858
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, single-center, open-label, umbrella-shaped phase II clinical study for patients with HR+/HER2- endocrine-resistant advanced breast cancer.
Timeline
- Start
- 2020-05-01
- Primary completion
- 2023-05-01
- Completion
- 2025-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Dalpiciclib | Small molecule | — | — |
| Subject | Everolimus | Small molecule | — | — |
| Subject | Famitinib | Small molecule | — | — |
| Subject | Fluzoparib | Small molecule | — | — |
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pyrotinib | Small molecule | — | — |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | — |
| Subject | Rezvilutamide | Small molecule | — | — |
| Subject | SHR2554 | Small molecule | — | — |
| Subject | SHR7390 | Unknown | — | — |